Gapping down
In reaction to disappointing earnings/guidance: CR -4.3%, PKG -1.4%, LMT-0.7%, MNRO -0.5%
Select China related names showing weakness after Shanghai -6% overnight: CEO -2.4%, VNET -1.8%, EDU -1.4%, SFUN -1%, JD -0.9%, YY-0.9%, BIDU -0.5%
Other news: EVEP -5.7% (announces reduction of quarterly cash distribution to $0.075 per unit, down from $0.50 in the prior quarter),ROYT -4.5% (announced there will be no cash distribution to the holders of its units for February), GLPG -4.2% (reports Phase 2a study of GLPG1205 results; primary endpoints not met; will discontinue clinical development in UC), CDI -2.6% (approves $20 mln buy back; eliminates quarterly dividend), CNC -1.9% (reported internal search of information technology assets), DDD -1.1% (likely in sympathy with SSYS dg)
Analyst comments: SSYS -3.7% (downgraded to Neutral from Overweight at JP Morgan), USG -2.8% (downgraded to Underperform from Neutral at Credit Suisse), PSA -1% (downgraded to Equal Weight from Overweight at Barclays)
In reaction to disappointing earnings/guidance: CR -4.3%, PKG -1.4%, LMT-0.7%, MNRO -0.5%
Select China related names showing weakness after Shanghai -6% overnight: CEO -2.4%, VNET -1.8%, EDU -1.4%, SFUN -1%, JD -0.9%, YY-0.9%, BIDU -0.5%
Other news: EVEP -5.7% (announces reduction of quarterly cash distribution to $0.075 per unit, down from $0.50 in the prior quarter),ROYT -4.5% (announced there will be no cash distribution to the holders of its units for February), GLPG -4.2% (reports Phase 2a study of GLPG1205 results; primary endpoints not met; will discontinue clinical development in UC), CDI -2.6% (approves $20 mln buy back; eliminates quarterly dividend), CNC -1.9% (reported internal search of information technology assets), DDD -1.1% (likely in sympathy with SSYS dg)
Analyst comments: SSYS -3.7% (downgraded to Neutral from Overweight at JP Morgan), USG -2.8% (downgraded to Underperform from Neutral at Credit Suisse), PSA -1% (downgraded to Equal Weight from Overweight at Barclays)